Table 1.

Relative Quantitative PCR for SPARC and Myocilin mRNA

	DMSO			Lat-B
	211	424	431	211	424	431
SPARC
5 kPa	0.74 ± 0.08a	0.36 ± 0.01a*	1.7 ± 0.30a	0.45 ± 0.05a*†	0.25 ± 0.01a*†	2.0 ± 0.60a
25 kPa	4.7 ± 1.7	4.6 ± 0.13b*	1.5 ± 0.21a	1.3 ± 0.07b*	3.4 ± 0.03b*†	0.81 ± 0.04a†
75 kPa	2.7 ± 0.45b	19 ± 1.4c*	140 ± 34b*	0.85 ± 0.10c†	8.5 ± 1.8b†	0.95 ± 0.08a†
TCP (>1 GPa)	1.0	1.0	1.0	0.9 ± 0.03	6.6 ± 0.3†	340 ± 140
Myocilin
5 kPa	1.7 ± 0.15a*	0.29 ± 0.05a*	0.54 ± 0.02a*	0.67 ± 0.03a*†	0.25 ± 0.05a*	0.32 ± 0.02a*†
25 kPa	5.3 ± 1.3a*	0.97 ± 0.12b	1.1 ± 0.03b	1.3 ± 0.08b*†	1.0 ± 0.04b*	0.97 ± 0.06b*
75 kPa	11.9 ± 0.39b*	170 ± 27c*	93 ± 1.7c*	1.8 ± 0.08c*†	19 ± 7.6†	1.3 ± 0.09c*†
TCP (>1 GPa)	1.0	1.0	1.0	0.95 ± 0.03	4.3 ± 0.6†	140 ± 13†

Relative quantification of mean ± SEM SPARC and myocilin mRNA for the HTM 211, 424, and 431 cells when grown on 5, 25, or 75 kPa hydrogels or TCP under control conditions (DMSO) or with 2 μM Lat-B. For each variable, different superscript letters mean significant effect between hydrogels (P < 0.05).

^*Statistically significant difference from the SPARC or myocilin mRNA on a hydrogel versus TCP (P < 0.05).

^†Statistically significant difference from the SPARC or myocilin mRNA following DMSO or Lat-B treatment (P < 0.05).